Cargando…
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Inflammation is a hallmark of cancer(1). In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across malignancies and therapeutic modalities(2–5). Whether myeloid inflammation drives...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686834/ https://www.ncbi.nlm.nih.gov/pubmed/37844613 http://dx.doi.org/10.1038/s41586-023-06696-z |